Company intelligence / Profile preview

AffyImmune Therapeutics

Natick, Massachusetts, United Statesaffyimmune.com ↗

Ownership: Private
Development stage: Phase 1

Overview

AffyImmune's lead candidate AIC100, an ICAM-1-directed CAR T therapy for advanced and anaplastic thyroid cancers, has shown safety in initial Phase I cohorts. The company received FDA RMAT designation based on preliminary evidence of efficacy and safety from the first ten patients dosed. One confirmed complete response was reported in a patient with anaplastic thyroid cancer. The pipeline targets additional solid tumors where ICAM-1 is overexpressed.[9][8]

Therapeutic areas: Oncology
Modalities: CAR T cellsCell therapy
Industry: Biotech

Drug pipeline

2 assets

AIC100

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AffyImmune Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AffyImmune Therapeutics.

Explore the full profile